Clinical trial · Observational
Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors
Troponin to Detect Major Cardiovasculaire Advserse Events on Immune: a Case Control Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recent guidelines suggest the use of troponin to detect immnune related cardiovascular advserse events in patients treated by immune checkpoint inhibitors for cancer. However, there is no proof that patients on immune checkpoint inhibitors benefit from this active surveillance strategy. The suspicion of cardiovascular events may lead to the interruption of cancer therapies. The TILT study aims at assessing: (i) the efficiency of troponin measurments in asymptomatic patients to prevent the further advent of major cardiovascular events; (ii) its safety in terms of cancer therapy completion.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cardiovascular Biomarkers | — | UNRESOLVED | — |
| Immune Checkpoint Inhibitor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Active surveillance by means of troponin measurements
- interventionNames
- Other: No intervention
- label
- No active surveillance by means of troponin measurements
Primary outcomes (1)
- measure
- Major cardiovascular event
- timeFrame
- 5 years
- description
- Acute coronary syndrome, stroke, myocarditis, heart failure, sustained ventricular arrhymias, cardiovascular death
Secondary outcomes (1)
- measure
- Completion of cancer therapy as scheduled
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All solid cancer patients treated by immune checkpoint inhibitors 2017-2022 Exclusion Criteria: * Patients enrolled in an invterventional study (e.g., pharma trial)
References
Publications (0)
Data not yet available